175136-30-8

Basic information

• Product Name: 2-(5-METHYL-2-PHENYLTHIAZOL-4-YL)ETHANOL
• Synonyms: 2-(5-METHYL-2-PHENYLTHIAZOL-4-YL)ETHANOL
• CAS NO: 175136-30-8
• Molecular Formula: C₁₂H₁₃NOS
• Molecular Weight: 219.31
• Mol File: 175136-30-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(5-METHYL-2-PHENYLTHIAZOL-4-YL)ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-METHYL-2-PHENYLTHIAZOL-4-YL)ETHANOL(175136-30-8)
• EPA Substance Registry System: 2-(5-METHYL-2-PHENYLTHIAZOL-4-YL)ETHANOL(175136-30-8)

Safety Data

• Hazardous Substances Data: 175136-30-8(Hazardous Substances Data)

Usage

General Description

2-(5-Methyl-2-phenylthiazol-4-yl)ethanol is a chemical compound with the molecular formula C12H13NOS. It is a thiazole derivative with a methyl and phenyl group attached to the thiazole ring. The compound is classified as an ethanol derivative due to the presence of the ethyl group. It is commonly used in the pharmaceutical industry for its potential therapeutic properties, including anti-inflammatory and antimicrobial effects. The compound may also have applications in the synthesis of organic molecules and as a building block for the development of new drugs. Additionally, its chemical structure and properties make it of interest for research in the fields of medicinal chemistry and drug discovery.

Upstream product

• 175136-29-5 2-[5-methyl-2-phenyl-1,3-thiazol-4-yl]acetic acid methyl ester 
• 2227-79-4 benzenecarbothioamide 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 36187-69-6 ethyl 4-bromo-3-oxopentanoate 

Downstream Products

• 196810-92-1 2(S)-<(2-benzoylphenyl)amino>-3-<4-<2-(5-methyl-2-phenylthiazol-4-yl)ethoxy>phenyl>propionic acid methyl ester 
• 521266-74-0 (2S)-1-{[2-(5-Methyl-2-phenyl-thiazol-4-yl)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile 
• 412007-74-0 ethyl 5-[2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)ethoxy]-1H-indole-2-carboxylate 
• 956091-34-2 C₂₅H₂₇NO₃S 

Relevant articles and documents

Aromatic heterocyclic small molecule organic compounds and derivatives, preparation method and medical use

The invention discloses heterocyclic aromatic micromolecule organic compounds as shown in the structural formula (I) and derivatives thereof, or hydrates or pharmaceutically acceptable salts, and a preparation method of the corresponding compounds; the invention also discloses an application of the compounds and pharmaceutical compositions containing the compounds to the treatment of various metabolic syndrome-related diseases. The heterocyclic aromatic micromolecule organic compounds of the invention have excellent treatment effect on metabolic syndromes; experiment results show that the compounds may promote secretion of endogenous GLP-1, and are applicable to the preparation of anti-diabetic and fat-reducing candidate medicaments. Aiming at technical problems of easy degradation and short half life of current medicaments for treating diabetes, the invention provides novel, high-efficient micromolecule compounds for promoting secretion of endogenous GLP-1, and the compounds are applicable to the treatment of metabolic syndrome-related diseases such as diabetes, obesity and the like.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Compounds represented by the following (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety

We previously reported the identification of (2S)-((2- benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-phenyloxazol-4- yl)ethoxy]phenyl}propanoic acid (2) (PPARγ pK(i) = 8.94, PPARγ pEC50 = 9.47) as a potent and selective PPARγ agonist. We now report the expanded structure-activity relationship around the phenyl alkyl ether moiety by pursuing both a classical medicinal chemistry approach and a solid-phase chemistry approach for analogue synthesis. The solution-phase strategy focused on evaluating the effects of oxazole and phenyl ring replacements of the 2-(5-methyl-2-phenyloxazol-4-yl)ethyl side chain of 2 with several replacements providing potent and selective PPARγ agonists with improved aqueous solubility. Specifically, replacement of the phenyl ring of the phenyloxazole moiety with a 4-pyridyl group to give 2(S)-((2- benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-pyridin-4-yloxazol-4- yl)ethoxy]phenyl}propionic acid (16) (PPARγ pK(i) = 8.85, PPARγ pEC50 = 8.74) or a 4-methylpiperazine to give 2(S)-((2-benzoylphenyl)amino)-3-(4- {2-[5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl]ethoxy}phenyl)propionic acid (24) (PPARγ pK(i) = 8.66, PPARγ pEC50 = 8.89) provided two potent and selective PPARγ agonists with increased solubility in pH 7.4 phosphate buffer and simulated gastric fluid as compared to 2. The second strategy took advantage of the speed and ease of parallel solid-phase analogue synthesis to generate a more diverse set of phenyl alkyl ethers which led to the identification of a number of novel, high-affinity PPARγ ligands (PPARγ pK(i)'s 6.98-8.03). The combined structure-activity data derived from the two strategies provide valuable insight on the requirements for PPARγ binding, functional activity, selectivity, and aqueous solubility.